It has never been a bigger problem than now: it is estimated that more than 800 million people have chronic kidney disease (CKD) and diabetes is the leading cause of CKD, all projections say that prevalence of both type 2 diabetes and CKD will increase in the coming years, and CKD is expected to become […]
Read MoreCategory: Diabetes
Diabetes Spotlight: Susan Bailey Gurley, MD, PhD—Charting Hypertension and Diabetic Nephropathy Through Mouse Models
A key question for scientists as they raced to understand SARS-CoV-2: what was the human entry point for the virus that causes COVID-19? The answer, angiotensin-converting enzyme 2 (ACE2), was a protein Susan Gurley had studied for decades, not as a virologist but as a nephrologist. “I still study ACE2 in the context of kidney […]
Read More
Special Edition: What's Next: Adherence to Medications – Challenges and (some) Solutions December 2025
In this special edition on Adherence to Medications our host, Dr. Neil Skolnik will discuss medication adherence and the role of clinicians, pharmacies and pharmacists in helping with medication adherence. This special episode is supported by an independent educational grant from Amazon. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel […]
Read More
Special Edition: MASH Part 2 – Diagnosis and Treatment – December 2025
In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss Epidemiology, Importance, Screening, Diagnosis and Treatment of MASH. This special episode is supported by an independent educational grant from Boehringer Ingelheim. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, […]
Read More
Special Edition – Automated Insulin Delivery – Part 1
In this special series on Automated Insulin Delivery our host, Dr. Neil Skolnik will discuss with Davida Kruger the benefits of Automated Insulin Delivery for people with Type 2 Diabetes. This special episode is supported by an independent educational grant from Insulet. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel […]
Read More
Diabetes Core Update – December 2025
This issue will review: 1. Screening Natriuretic Peptide Levels Predict Heart Failure and Mortality in Individuals with Type 1 and Type 2 Diabetes without Known Heart Failure 2. The Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications In Patients with Type 2 Diabetes 3. Continuous Glucose Monitoring Frequency and Glycemic Control […]
Read MoreMetabolic and Paracrine Heterogeneity of Pancreatic Glucagon-Secreting α-Cells
By stimulating hepatic glucose production, glucagon (released by islet α-cells) restores normal blood glucose levels when they fall below the normal range. We used optogenetics in conjunction with electrophysiology, cytoplasmic free Ca2+ concentration imaging, and hormone release measurements to explore the intrinsic and paracrine regulation of glucagon secretion. Many α-cells were spontaneously active at 1 […]
Read MoreThe Benefits of Exercise Training in Combination With Weight Loss Therapies
The primary treatment for obesity involves calorie restriction (CR) to promote dietary weight loss achieved through interventions including behavioral modification, bariatric surgery, and antiobesity medications. In adults with obesity, CR-induced weight loss enhances physical function and improves quality of life, while also reducing the burden of various obesity-related chronic conditions, including hypertension, diabetes, obstructive sleep […]
Read MoreHigh-Quality Weight Loss in Obesity: Importance of Skeletal Muscle
Treatment responses to behavioral, surgical, and pharmacological approaches in obesity are highly variable in quantity and quality. Here we refer to high-quality weight loss as a high proportion of fat to skeletal muscle mass lost. Given the role of skeletal muscle in energy expenditure, glucose homeostasis, metabolic flexibility, mobility, and strength, excessive loss of skeletal […]
Read MoreTreating Sarcopenic Obesity in the Era of Incretin Therapies: Perspectives and Challenges
Sarcopenic obesity, a subtype of obesity, is marked by reduced skeletal muscle mass and function, or sarcopenia, and poses a significant health challenge to older adults as it affects an estimated 28.3% of people aged >60 years. This subtype is unique to older adults as aging exacerbates sarcopenia and obesity due to changes in energy […]
Read More